Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7390791 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(1 year, 19 days from now) | |
US8754065 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
US9296769 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7803788 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucoleotide analogues |
Feb, 2022
(2 years ago) | |
US7390791 (Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Oct, 2025
(1 year, 6 months from now) | |
US9296769 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
US8754065 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) |
Descovy is owned by Gilead Sciences Inc.
Descovy contains Emtricitabine; Tenofovir Alafenamide Fumarate.
Descovy has a total of 7 drug patents out of which 1 drug patent has expired.
Expired drug patents of Descovy are:
Descovy was authorised for market use on 04 April, 2016.
Descovy is available in tablet;oral dosage forms.
Descovy can be used as treatment of hiv infection; prophylaxis of hiv-1 infection; treatment of hiv-1 infection, treatment of hiv-1 infection, prophylaxis of hiv-1 infection; treatment of hiv-1 infection; treatment of hiv infection.
The generics of Descovy are possible to be released after 15 February, 2033.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jan 7, 2029 |
Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient
Market Authorisation Date: 04 April, 2016
Treatment: Treatment of hiv-1 infection; Prophylaxis of hiv-1 infection; Treatment of hiv infection
Dosage: TABLET;ORAL